Nm23 protein expression in metastatic and non-metastatic tongue squamous cell carcinoma

Éricka Janine Dantas Da Silveira,Márcio Campos Oliveira,Maria De Lourdes Silva Arruda De Morais,Lélia Maria Guedes Queiroz,Antonio De Lisboa Lopes Costa

doi:10.1016/s1808-8694(15)30568-1

Abstract

SummaryOral squamous cells carcinoma (OSCC) shows unfavorable prognosis due to its invasion potential around the neighboring tissues and the elevated incidence of metastasis.Aimthe present paper aims at analyzing the immunohistochemical expression of the nm23 protein in metastatic and non-metastatic SCCs of tongue.Methodsthe immuno-expression to the nm23-hl protein was diagnosed in 35 tongue SCC (15 of which exhibiting metastasis). Nm23-hl immuno-scores were assigned as follow: score 0 = absent, 1 = focal and 2 = diffuse expression.ResultsThe Fisher's exact test was performed and there was no statistical difference between the nm23-hl immuno-scores and the tongue SCCs studied cases (p=0.365), although 66.7% of metastatic cases presented negative nm23-hl expression.ConclusionsProtein nm23 was not associated with a positiveness for tongue SCC without metastasis. Thus, several others factors inherent to host and malignancy can be associated with the mechanisms that suppress the metastatic process in this disease.

Highlights

Head and neck carcinomas are the sixth most common cancer worldwide (INCA, 2006),[1] the oral squamous cell carcinoma (OSCC) is the most frequent malignancy in this region
The purpose of this paper was to assess the immunohistochemical expression of the nm23-h1 protein in metastatic and non-metastatic squamous cell carcinomas of the tongue
Those authors found that mRNA levels for both the nm23-h1 and the nm23-h2 were decreased in the MDA-MB435 metastatic cell line, compared to the non-metastatic line

Summary

Introduction

Head and neck carcinomas are the sixth most common cancer worldwide (INCA, 2006),[1] the oral squamous cell carcinoma (OSCC) is the most frequent malignancy in this region. The prognosis of this entity in the mouth is poor; the local invasion and cervical lymph node metastasis rates are high.[2,3]. Even with advances in oncological therapy, the five-year survival rate for patients with invasive OSCCs remains low (about 35%) Such morbidity rates may be due to factors such as varied responses to chemotherapy and radiotherapy, late presentation and delayed diagnosis. Neck lymph node metastases and the TNM are the main measures of tumor aggressiveness, and are important parameters for planning the approach to such cases

Objectives

Methods

Results

Conclusion